Sec Form 4 Filing - Todisco Joseph @ Amneal Pharmaceuticals, Inc. - 2022-03-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Todisco Joseph 2. Issuer Name and Ticker or Trading Symbol Amneal Pharmaceuticals, Inc. [ AMRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Executive Vice President (Last) (First) (Middle) C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD 3. Date of Earliest Transaction (MM/DD/YY) 03/01/2022 (Street) BRIDGEWATER, NJ08807 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Common Stock 03/01/2022 M 11,111( 1 ) A 311,007 D Class A Common Stock 03/01/2022 F 3,906( 3 ) D $ 4.45 307,101 D Class A Common Stock 03/01/2022 M 26,544( 1 ) A 333,645 D Class A Common Stock 03/01/2022 F 9,331( 3 ) D $ 4.45 324,314 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units ( 2 ) 03/01/2022 M 11,111 ( 4 ) ( 4 ) Class A Common Stock 11,111 $ 0 11,111 D Restricted Stock Units ( 2 ) 03/01/2022 M 26,544 ( 5 ) ( 5 ) Class A Common Stock 26,544 $ 0 79,634 D Restricted Stock Units ( 2 ) 03/03/2022 A 144,928 ( 6 ) ( 6 ) Class A Common Stock 144,928 $ 0 144,928 D Performance-Based Restricted Stock Units ( 7 ) 03/03/2022 A 289,856( 8 ) ( 8 ) ( 8 ) Class A Common Stock 289,856( 8 ) $ 0 289,856( 8 ) D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Todisco Joseph C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD BRIDGEWATER, NJ08807 Executive Vice President Signatures /s/ Meredith Cook, Attorney-in-Fact 03/03/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. ( 2 )Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock. ( 3 )Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. ( 4 )On March 1, 2019, the reporting person was granted 44,444 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. ( 5 )On March 1, 2021, the reporting person was granted 106,178 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. ( 6 )The restricted stock units vest in four equal annual installments beginning on March 3, 2023. ( 7 )Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. ( 8 )Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.